ANDAINTRAVESICALSOLUTION
Approved
Apr 2019
Lifecycle
Post-LOE
Competitive Pressure
30/100
Data completeness
2/8 — Basic
VALRUBICIN (valrubicin intravesical solution) by Hikma is functions, most of which involve nucleic acid metabolism. First approved in 2019.
Drug data last refreshed 18h ago
Mechanism of Action
functions, most of which involve nucleic acid metabolism. In cells, it inhibits the incorporation of nucleosides into nucleic acids, causes chromosomal damage, and arrests the cell cycle in G 2 . Although valrubicin does not bind strongly to DNA, valrubicin metabolites interfere with the normal DNA…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Company
Hikma
NJ - Berkeley Heights
Worked on VALRUBICIN at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.